GRI Bio, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $4.0M
- Price
- $1.85
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.63%
- Volume
- 32.7K
About
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Quick stats
Shares outstanding2.2M
Computed float2.2M
Float / shares100.0%
Cash runway (months)9.5
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001824293
Websitehttps://www.gribio.com
AI Summary
AI-generated1/17
minorneutraloperations update
GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit
GRI Bio announced that CEO Marc Hertz and CSO Vipin Kumar will present at the 10th IPF Summit in Boston, September 29 to October 1, 2026.
The presentations cover immune biology in idiopathic pulmonary fibrosis and insights from Phase 2a development of GRI-0621, the company's oral RAR beta/gamma-selective agonist for IPF.
Management described the Phase 2a findings as encouraging across lung function, biomarkers and tolerability, but no new data were disclosed in this release.
Red flags
- Company notes substantial additional capital will be required to fund a Phase 2b trial of GRI-0621
- Risk factor: potential inability to maintain Nasdaq listing